GKOS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

122.830

Open

120.140

VWAP

119.00

Vol

277.00K

Mkt Cap

7.00B

Low

116.690

Amount

33.00M

EV/EBITDA(TTM)

Total Shares

57.00M

7.00B

EV/OCF(TTM)

P/S(TTM)

14.00

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Events Timeline

(ET)

2026-01-28

07:30:00

Glaukos Receives FDA Approval for iDose TR Re-administration

2026-01-14 (ET)

2026-01-14

10:10:00

Glaukos Shares Down 8.5% to $100.85

2026-01-13 (ET)

2026-01-13

19:20:00

U.S. Stocks End Tuesday Lower, JPMorgan Earnings Impact Notable

2026-01-13

16:10:00

Glaukos Sees Q4 Glaucoma Net Sales Around $86M

2026-01-13

16:10:00

Company Ends Q4 2025 with Approximately $283M in Cash

News

9.0

01-28Yahoo Finance

PinnedGlaukos Receives FDA Approval for iDose TR Re-Administration

8.5

01-28Newsfilter

PinnedGlaukos Receives FDA Approval for iDose TR Re-Administration

9.0

01-28seekingalpha

Glaukos iDose TR Receives FDA Labeling Approval

4.5

01-15NASDAQ.COM

S&P 500 Index Falls 0.53% as Tech Stocks Weigh Down Market

4.5

01-14NASDAQ.COM

S&P 500, Dow, and Nasdaq Decline Amid Rising Geopolitical Risks

4.5

01-14NASDAQ.COM

S&P 500, Dow, and Nasdaq Decline; Nasdaq Hits One-Week Low

13 Analyst Rating

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

1 Sell

Strong Buy

Current: 0.000

Low

72.00

Averages

127.08

High

165.00

Current: 0.000

Low

72.00

Averages

127.08

High

165.00

Wells Fargo

Overweight

maintain

$122

AI Analysis

2026-01-28

New

Reason

Wells Fargo

Price Target

$122

AI Analysis

2026-01-28

New

maintain

Overweight

Reason

Wells Fargo notes that Glaukos has announced FDA approval of its repeat dosing label for iDose, in line with the firm's expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.

BTIG

Buy

maintain

$123 -> $131

2026-01-28

New

Reason

BTIG

Price Target

$123 -> $131

2026-01-28

New

maintain

Buy

Reason

BTIG raised the firm's price target on Glaukos to $131 from $123 and keeps a Buy rating on the shares after the company announced FDA approval allowing for repeat treatments of iDose. Glaukos now has a much broader label for iDose than the prior label, which was limited to one iDose per eye, the analyst tells investors in a research note. BTIG believes the approval gives the company "significant optionality" in the interventional glaucoma space.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GKOS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Glaukos Corp (GKOS.N) is -198.99, compared to its 5-year average forward P/E of -65.18. For a more detailed relative valuation and DCF analysis to assess Glaukos Corp 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-65.18

Current PE

-198.99

Overvalued PE

-17.66

Undervalued PE

-112.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-552.46

Current EV/EBITDA

-1373.43

Overvalued EV/EBITDA

2390.74

Undervalued EV/EBITDA

-3495.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.06

Current PS

11.13

Overvalued PS

14.31

Undervalued PS

7.81

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what can I invest to make fast cash

Intellectia · 102 candidates

Market Cap: 2.00B - 20.00BRsi Category: moderateRelative Vol: >= 1.20Beta: ModerateRisk, HighRiskWeek Price Change Pct: >= $3.00

Ticker

Name

Market Cap$

GKOS

Glaukos Corp

7.00B

BRBR

Bellring Brands Inc

3.00B

PLAB

Photronics Inc

2.00B

SMCI

Super Micro Computer Inc

19.00B

MYRG

MYR Group Inc

4.00B

GPOR

Gulfport Energy Corp

4.00B

best stocks to buy call options in now

Intellectia · 159 candidates

Rsi 14: 30 - 70Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00Is Optionable: TrueOption Sentiments: Bullish

Ticker

Name

Market Cap$

ILMN

Illumina Inc

23.00B

VIV

Telefonica Brasil SA

21.00B

GLXY

Galaxy Digital Inc

13.00B

GIL

Gildan Activewear Inc

12.00B

IAG

IAMGOLD Corp

11.00B

TIGO

Millicom International Cellular SA

10.00B

Whales Holding GKOS

Sofinnova Investment, Inc.

Westfield Capital Management Company, L.P.

Riverbridge Partners, LLC

Osterweis Capital Management, Inc.

Granite Investment Partners, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Glaukos Corp (GKOS) stock price today?

The current price of GKOS is 117.93 USD — it has decreased -0.96 % in the last trading day.

What is Glaukos Corp (GKOS)'s business?

What is the price predicton of GKOS Stock?

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Glaukos Corp (GKOS)'s revenue for the last quarter?

Glaukos Corp revenue for the last quarter amounts to 134.00M USD, increased 38.14 % YoY.

What is Glaukos Corp (GKOS)'s earnings per share (EPS) for the last quarter?

Glaukos Corp. EPS for the last quarter amounts to -0.28 USD, decreased -28.21 % YoY.

How many employees does Glaukos Corp (GKOS). have?

Glaukos Corp (GKOS) has 995 emplpoyees as of January 30 2026.

What is Glaukos Corp (GKOS) market cap?

Today GKOS has the market capitalization of 7.00B USD.

GKOS Overview

GKOS Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding GKOS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Glaukos Corp (GKOS) stock price today?

What is Glaukos Corp (GKOS)'s business?

What is the price predicton of GKOS Stock?

What is Glaukos Corp (GKOS)'s revenue for the last quarter?

What is Glaukos Corp (GKOS)'s earnings per share (EPS) for the last quarter?

How many employees does Glaukos Corp (GKOS). have?

What is Glaukos Corp (GKOS) market cap?